Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock performance over the past month tells a different story, declining ...

Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today. The company’s shares closed last ...

The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving ...

The fifth-largest healthcare stock in the S&P 500 Index ($SPX) is proving that just because a stock is down 30%, it’s not a ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

The best value stocks have an attractive fundamental valuation, a healthy balance sheet, a stable or growing market share in ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...